Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

MannKind

NASDAQ MNKD
$4.59 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 30 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

1.49B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
1.53B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.93
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
324.73M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
26.10 %

Upcoming events MannKind

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart MannKind

Stock analysis MannKind

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
175.62 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
-6.05 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
39.39 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.08 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-3.69 7.67

Price change MannKind per year

1.84$ 6.25$
Min Max

Summary analysis MannKind

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure MannKind

Revenue and net income MannKind

All parameters

Stock news MannKind

All news
2 January в 22:50

MannKind Shares Rise 6.6% After Selling 1% Royalty Interest In Tyvaso DPI

2 January в 22:50

MannKind Shares Rise 6.6% After Selling 1% Royalty Interest In Tyvaso DPI

2 January в 14:35

MannKind Sells Part of Tyvaso DPI Royalties for Up to $200 Million

2 January в 14:25

MannKind in royalty agreement with Sagard Healthcare for Tyvaso DPI

28 December 2023 в 01:05

MannKind Modifies Supply Agreement With Amphastar

28 December 2023 в 01:05

MannKind Modifies Supply Agreement With Amphastar

10 October 2023 в 14:41

MannKind initiated with outperform rating and 12-month price target of $10 at Wedbush Securities

3 July 2023 в 15:35

MannKind shares fall after fire that may delay clinical trial

23 January 2023 в 14:36

MannKind's MNKD-101 to Advance to Phase2/3 Study

23 January 2023 в 14:36

MannKind's MNKD-101 to Advance to Phase2/3 Study

23 May 2022 в 21:43

MannKind, United Therapeutics Rise on FDA Approval of Tyvaso DPI

23 May 2022 в 21:43

MannKind, United Therapeutics Rise on FDA Approval of Tyvaso DPI

17 May 2022 в 20:11

Zealand Pharma Shares Rise 13% After MannKind Buys V-Go Insulin Delivery Device

17 May 2022 в 20:11

Zealand Pharma Shares Rise 13% After MannKind Buys V-Go Insulin Delivery Device

17 May 2022 в 13:21

MannKind Buys V-Go Insulin Device From Zealand Pharma For $10M, Milestones

17 May 2022 в 13:21

MannKind Buys V-Go Insulin Device From Zealand Pharma For $10M, Milestones

24 February 2022 в 19:30

MannKind Shares Slump 20% After Delay in FDA Review of Tyvaso DPI

24 February 2022 в 19:30

MannKind Shares Slump 20% After Delay in FDA Review of Tyvaso DPI

18 October 2021 в 18:47

MannKind's stock falls 18% after FDA says it will not approve application for hypertension drug

About company MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-ß inhibitor for the treatment of pulmonary fibrosis. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Address:
30930 Russell Ranch Road, Westlake Village, CA, United States, 91362
Company name: MannKind
Issuer ticker: MNKD
ISIN: US56400P7069
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2004-07-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.mannkindcorp.com

On which stock exchange are MannKind (MNKD) stocks traded?

MannKind (MNKD) stocks are traded on NASDAQ.

What is the ticker of MannKind stocks (MNKD)?

The stock ticker of MannKind’s stocks or in other words, the code is MNKD. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does MannKind (MNKD) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, MannKind (MNKD) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are MannKind (MNKD) stocks traded?

MannKind (MNKD) stocks are traded on the NASDAQ exchange in dollars.

What is the price of MannKind (MNKD) stocks today?

The current price of MannKind stocks on 20.05.2024 is 4.59 dollars. per share.

What is the dynamics of MannKind (MNKD) stocks from the beginning of the year?

MannKind (MNKD) quotes have increased by 17.09% from the beginning of the year up to 4.59 dollars. per 1 stocks.

How much did MannKind (MNKD) stocks increase in мае 2024?

This month MannKind (MNKD) quotes have increased by 5.76% to 4.59 dollars. per share.

How much are MannKind (MNKD) stocks worth?

Today, on October, 20.05.2024 MannKind’s (MNKD) stocks cost 4.59 dollars..

What is the market capitalization of MannKind (MNKD)?

Capitalization is the market value of MannKind (MNKD) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of MannKind (MNKD) is estimated at about 1490524470 dollars.